Across TCGA pan-cancer cohorts, FBXO41 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FBXO41 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher FBXO41 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO41 expression acts as an unfavorable survival marker.
BRCA, HNSC, and ESCA are the cancer types where FBXO41 Mutation most reproducibly stratifies survival.